Response Genetics, Inc. (RGDX), a California-based life-science company, Thursday said it entered into a private purchase agreement with GlaxoSmithKline (GSK) and one of its stockholders to raise $8.8 million through the private placement of 8 million issued common shares of Response, for a price of $1.10 per share.
Thomas Bologna, chairman and CEO of Response Genetics stated, "The capital raised will help support our continued efforts in building a sustainable business of high value genetic tests for cancer patients as well as a premier pharmaceutical services business."
The signing of the purchase agreement and closing of the financing occurred on September 13, 2012.
Response Genetics shares are currently up 21.11%, trading at $1.09 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.